Generic Paxil Suicide Lawsuit


Citizens Commission on Human Rights Award Recipient (Twice)
Humanist, humorist

Thursday, April 19, 2018

Stop It!



Dr. Clare Gerada ~ "Stop it"

Louis Appleby, Government Advisor on the prevention of suicide, opened a can of worms on Twitter last month when he tweeted:


What followed were some jaw-dropping tweets from, Clare Gerada, the person Appleby was promoting.

Who is Clare Gerada?

Clare Gerada is one-half of a psych drug promotion pair. She's married to Simon Wessely, a psychiatrist and professor of psychological medicine at the Institute of Psychiatry, King's College London. Gerada was the chairperson of the Council of the Royal College of General Practitioners from 2010 to 2013. She is also a partner in the Hurley Group which runs a number of GP practices and walk-in centers across London. She was made a Member of the Order of the British Empire in the 2000 Birthday Honours "for service to medicine and to drug misusers"

Nice.

Now let's take a look at Clare's attempts to stifle conversation about the side effects surrounding 'antidepressants'.

First up to tweet opposition to her views was Australian Army Major Stuart McCarthy. He joined the Australian Army in 1988 and in 1999 deployed to Bougainville, Papua New Guinea where he served as commander of a multi-national patrol in the Peace Monitoring Group.

Towards the end of McCarthy’s Bougainville deployment, he became a subject in an unethical drug trial for the antimalarial drug tafenoquine. In 2001, he spent six months as the deputy force engineer in the United Nations Mission in Ethiopia and Eritrea. While there he was prescribed mefloquine and experienced a variety of adverse drug effects including depression.

Despite recurrent major depression and other debilitating neurological symptoms that he now realises are the result of the undiagnosed neurotoxic brain injury he sustained in 2001, McCarthy served in the Army for 16 additional years.

His full bio is at the foot of this blog post.

McCarthy's April 16th tweet to Gerada asked her three questions. The resulting twitter exchange was priceless despite that Gerada's "responses" were dreadfully predictable.

Click on Twitter images to enlarge.


Undeterred, Major McCarthy pressed Gerada for some answers. Once again, she tried to silence the respected veteran:


I then tweeted Gerada a question asking if she would concede that, for some, they (drugs labeled antidepressants) could be dangerous? Her reply, if you could call it such, was quite puzzling:

So, now she was using her same line on me, Gerada ordered me to "stop it."

Minutes later she made a claim that these drugs save lives and told me to read the 500 clinical trials that prove it. Ahem, I hated to break the following to her:





Gerada could not answer my question because the fact is there have been no clinical trials for drugs labeled antidepressants that supported the claim Gerada made. There are no clinical trials that have found any evidence that taking these drugs saves lives. If there were, pharmaceutical companies would have already printed this bold proclamation on their product packaging. Pharma would never let such a sales and promotional opportunity slip by.

After running face first into a brick wall, Gerada's next tweet was equally lame but more bizarre:

I've previously written about how critics of patient safety advocates throw out the PR stigma line. You can read all about it here.

I then pointed out Gerada's strawman arguments and her shady goal to suppress and shame those harmed by drugs labeled antidepressants. Fiona French, who has been seriously damaged by benzo prescribing, joined the twitter conversation. What is astounding here is the way Gerada diagnoses French.




The conversation seemed to end there, but the following morning Gerada tweeted something even more delusional.

My answer was short and sweet. "Stop it", I said.

Coming late to the twitter round was Kristina Gehrki. Her tweets appeared to have ended Gerada's nonsense. Perhaps Gerada was too busy the last days with her googling "Who is Florence Nightingale?"




**STOP PRESS**

Remarkably, just minutes ago, Gerada felt the need to chip in again. This time, responding to a parent whose son died in an 'antidepressant' induced death. Telling a parent whose child died as a result of a prescription that they are 'wrong' is an affront to public health. Her reply also shows an appalling lack of human compassion.

Here's the tweet.



Gerada has now blocked me on Twitter.

Bob Fiddaman












Monday, April 16, 2018

India: GSK Whistleblower Names and Shames - Part II






"This was not just a violation of the standard operating procedures and code of conduct at GSK but also violated several sections of the Constitution of India and Penal Code."

Following on from Part I

In summary, Navneet Kumar, a rep for GSK India, is blowing the whistle on the way the company operates its business out of India.

In Part I, we learned that Kumar was told by senior management to meet his targets by "hook or by crook". Further, Kumar was paying stockists out of his own pocket so senior management would reap the monetary benefits. This despite the GSK rule book stipulating that: "a drug rep should not be involved in any money-related matters with their stockists."

Kumar filed a complaint against his Regional Business Manager, Sanjeev Jolly, who apologized and, well, that was that. GSK officials took no disciplinary action against Jolly.



Part I also highlighted how Kumar's  Area Business Manager (ABM), Jitendra Singh Chauhan (pictured above), would phone him after midnight making demands - he'd even phone Kumar whilst he was on leave. Kumar didn't comply with the demands and was summoned to a meeting at GSK's New Delhi office by Sanjeev Jolly, who asked Kumar to resign. When he refused, Jolly told him, "I will finish your career" and that, "You and your family will be out on the street."

Part II

Because Kumar didn't resign he was issued a charge sheet. It's here that he alleges GSK management created trumped up charges against him because he had brought it to their attention about violations within the company, more specifically his senior management.

Whenever a charge sheet is issued against an employee, that employee has a right to be accompanied by a co-worker or a legal representative. Kumar told me:
"After the charge- sheet was issued, I requested to GSK management to allow me legal representation because of the allegations against me. My request of legal representation was denied by GSK management. So I fought  my case alone  in the enquiry proceedings. The charge sheet alleged they had witnesses but no such witnesses were ever provided by GSK. The enquiry officer was Vipin laroia and from the early stages of the enquiry it appeared he was siding with GSK management."
In fact, according to Kumar, The investigation was trying to hide the witness statements from him. He later learned that the only witnesses GSK had were the two senior managers who had harassed him from the get-go.

Kumar wrote to senior management and asked if they could change the investigating officer, they refused.

Kumar was once again summoned, once again, he was asked to resign, once again, he refused.

Of that meeting Kumar told me:

"Somewhere I noticed that they weren't recording whatever I was saying, which was most disturbed me. Actually, as per the domestic enquiry rules, the job of recorder is to type the ongoing conversation on his laptop, but under the shadow of the enquiry officer and general manager they were acting like that they were typing but at end of enquiry proceedings they only provided me with what management had stated, and not what I had stated. They had also omitted the threats and their calls for me to resign."

Aniruddha Kunte, GSK General Manager -Employee Relations

Kumar, once again, sought help from higher management, this time writing to Aniruddha Kunte, General Manager -Employee Relations.

Kunte told him that after investigating the claims (which surmounted to asking the Inquiry Officers whether or not they were true) he (Kunte) found no evidence that suggested Kumar was being harassed, further, Kumar was told that he should "actively participate in the ongoing Inquiry."

Kumar told me he signed papers under duress as he felt intimated. He wrote, once again to Kunte:

(Email has been altered by me, Bob Fiddaman, for clarity)

Re: The last inquiry session on 10/8/2016 at the Delhi office.

The proceedings of that day were signed by me under duress. Some issues are the same as I told you earlier. But no action was ever taken by you.

The behavior of Mr. Vipin(EO) was the same. He was trying his best to harass me, he is totally under the influence of management.

During the meeting, Mr. Jolly was trying his best to put unnecessary pressure on me. Even when I told him that I was disturbed by his actions he didn't change his behavior and continued to humiliate me.

Therefore, I am requesting you to please make arrangements of a video recording of the Inquiry session.

Regards 
Navneet Yadav (Kumar)


--

Kunte never followed up and, more importantly, never provided the video recording to Kumar.

The charges against Kumar stood and at this point, he was joined in 'the field' by his ABM Jitendra Singh Chauhan. Basically, Chauhan would follow Kumar around to see if he was meeting his company objectives, which included meeting doctors and dealers as per company guidelines.

Kumar claims that on day one, Chauhan wasted 2 hours of the day in efforts to make Kumar's daily targets impossible. Kumar also alleges that Chauhan would take company vehicles off other reps which resulted in those reps not being able to meet their targets, he even, at times, according to Kumar, used to demand Kumar's car and bike for personal use. Once again, Kumar brought this to the attention of GSK's employee relations manager, once again, nothing was done.

Chauhan continued to waste time, resulting in Kumar not being able to meet his company objectives. Because of this, and because of the restrictions placed on in, Kumar invited Chauhan to ride with him in the evening - he failed to respond to any of Kumar's text messages suggesting this.

Enter the Handwriting Expert

The charges against Kumar continued, in fact, according to Kumar, he had to endure 10 inquiry sessions. On one such occasion, they accused him of not visiting a doctor that he claimed he had. GSK management claimed that the doctor was out of India at the time so Kumar could not have visited him. Kumar, in his defense, told me:
"I requested that the Inquiry Officer and Management Representative provide evidence in support of their allegation that the doctor was not present in India. After a while they produced a letter purportedly from the doctor. In it, he had written that he was indeed out of the country."
Regarding the apparent letter, Kumar told me:
"I examined that letter very carefully and I realized that it wasn’t written by the doctor. The handwriting matched that of my Area Business Manager, Jitendra Singh Chauhan. I brought this to the attention of the Enquiry Officer who quickly dismissed it."
After this, Kumar acquired the services of a certified handwriting expert who came to the conclusion that the apparent letter from the doctor was, in fact, the same handwriting as Kumar's ABM, Jitendra Singh Chauhan. Armed with this evidence, Kumar showed the Investigating Officer at yet another Inquiry session. He told me:
"In a closed inquiry session room, they abused me and threatened me. I tried to submit my expert handwriting report but they wouldn't accept it from me. Had they accepted it,  they would have seen clearly that Jitendra Singh Chauhan, with the assistance of  Sanjeev Jolly, forged the letter. This was not just a violation of the standard operating procedures and code of conduct at GSK but also violated several sections of the Constitution of India and Penal Code."
Compare two letters and judge for yourself. Were they, as the handwriting expert suggested, both written by the same hand? (Click image to enlarge)

The top is an example of Kumar's Area Business Manager, Jitendra Singh Chauhan, whilst the bottom is, apparently, from the doctor who, it is alleged, was out of the country.


Click Image to Enlarge

Kumar was dismissed from his position at GSK.

Shortly before his dismissal, Kumar sent emails to GSK's Global Head of Investigations, Jason Lord, and GSK's then chief, Andrew Witty. Included in his emails was the handwriting expert report (below) 



Those emails and responses coming up in Part III

Bob Fiddaman















Thursday, April 12, 2018

The Truth About SSRI Withdrawal/Dependence




The following legal brief has rarely been seen by members of the public. Read through it and you'll understand why.

It's a fascinating read and highlights just how GSK hid the withdrawal issues surrounding their popular antidepressant, Paxil.

Many readers will find the following PDF too much to bear. Many will be angered by it, and rightly so. I hope many of you will pass it on to family, friends and even healthcare professionals.

For me, at least, it's the most damning document to ever surface out of litigation. The litigation in question saw GlaxoSmithKline settle with over 3,000 plaintiffs who had struggled to taper off Paxil. Much of the evidence was sealed as part of the 'gagging order' - However, this legal brief gives us an insight into the incestuous relationship between GSK and the FDA. It also shows us how GSK carefully manipulated the system thus putting thousands of future patients through utter misery with debilitating side-effects of withdrawal.

The Yugoslavia trials, mentioned in the document below, are very interesting. Glaxo sponsored the two phases of these trials. In Phase I all patients were given Paxil, in Phase II some were switched to placebo. It was at this stage that the placebo patients began experiencing severe withdrawal issues. Glaxo chose to define this as "relapse" data. This would give them the ammunition to announce later that patients who stayed on Paxil continued to enjoy a normal, "depression free" life, but those abandoning the drug would suffer relapse back into a depressive state.

Back in 2015 I, under the Freedom of Information Act, requested from the MHRA the protocol for this particular clinical trial and whether or not that protocol included information and/or guidance on Paxil withdrawal. The MHRA wrote me and said they "didn't hold that information."

Here's the legal brief.

If you are having trouble viewing it then click here



Bob Fiddaman

Original Source






Sunday, April 08, 2018

The NYT Addresses Antidepressant Withdrawal Issues





The Lame Defense

You'll hear many lines when discussing the problem of withdrawing from drugs labeled "antidepressants." They include the following:

"These drugs save lives."
"Without them, I wouldn't be here."
"Antidepressants benefit millions of people worldwide."
"They help people get through their daily routine."

While it's not for me to rebut all the above claims, the real issues are that none of the above lines have any relevance into discussing the challenges of "antidepressant" drug withdrawal. Comments such as the above are designed to get people to focus on the purported benefits of "antidepressants" and reduce discussion and/or dismiss discussion about the known risks. These lines are spouted by pharmaceutical companies, pharma-funded "health" and suicide organizations, drug regulators, doctors and consumers of "antidepressants." Some consumers, simply don't care about others who struggle with horrendous and life-threatening adverse drug reactions (ADRs). Perhaps these consumers of "antidepressants" are too frightened to look at the statistics for if they did, many would try to get off these drugs and would then find themselves gaining first-hand experience with SSRI ADRs.

Shifting the blame

If the above illogical responses don't work then the same people use the "shifting the blame" tactic. Some of these tactics include:

"Talk to your doctor."
"You're obviously not ready to come off them yet."
"It's not withdrawal, it's a return of your mental illness."
"Don't believe everything you read on the internet."
"Stop pill-shaming."
"You're a conspiracy theorist."
"Don't you think if these drugs were dangerous someone would have spoken up about them?"

I've heard all these retorts and imagine you've heard some, too. Once again, these retorts are thrown out willy-nilly in an illogical attempt to reduce honest discussion and purposeful action to solve the withdrawal problem caused by drugs labeled "antidepressants." It's an illogical argument and a selfish "I'm alright, Jack" response.

Many people who chant the above retorts state ADRs only happen to a "handful" of people. Even if this were true, how would the claims above help those suffering from severe "antidepressant" ADR's? Does society believe there is a certain magic number of victims that have to be reached before wanting to reduce avoidable suffering? How many people have to die from SSRI ADRs before it is deemed a public health issue worthy of positive action? Are some lives more important than other lives? Considering children and the elderly are two groups most at risk for ADRs, is this a sign our society cares less about children and the elderly?

Do we have to wait until we have inconclusive evidence that shows antidepressants cause severe ADRs in more than half of those who take them?

Time for Broader Discussions

Yesterday, the New York Times published an article entitled, "Many People Taking Antidepressants Discover They Cannot Quit." It's a decent article and the authors, Benedict Carey and Robert Gebeloff, seem to have done their homework with one exception. They stated, "withdrawal has never been a focus of drug-makers or government regulators." This is not accurate and I'll tell you why:

The Yugoslavia Trials 

The Yugoslavia Trials did, indeed, flag the issue of withdrawal surrounding paroxetine (Paxil, Seroxat).

In summary, in 1988 GSK, then SmithKline Beecham (SKB) sponsored clinical trials in Yugoslavia. The purpose of the trials was to show how paroxetine could, when stopped, cause a relapse in depression. SKB never took into account that those relapsing (after stopping paroxetine) could have been suffering withdrawal symptoms.With the results they wanted, SKB then provided the FDA with apparent evidence that showed patients staying on Paxil continued to enjoy a normal, "depression free" life, but that those abandoning the drug would suffer relapse back into a depressive state.

One thing that irked SKB was that they had to convince the FDA that relapses shown in the study were not simply patients suffering withdrawal.
(You can read my coverage of the Yugoslavia trials at the foot of this post.)

Buck-Passing

Further, back in 2011, the British equivalent of the FDA, the MHRA, launched an "innovative" SSRI Learning Module for prescribing doctors. In it, they stated...
"Symptoms after sudden SSRI discontinuation usually last about one to two weeks and then resolve spontaneously, but they can persist for longer in some patients. Close clinical observation is required to ensure that withdrawal symptoms are not getting worse. Severe cases may call for specialist advice and possible switch to an SSRI with longer half-life before gradual tapering."
I was interested in the "specialist advice" they were recommending to doctors who had patients suffering from worsening withdrawal symptoms. I, therefore, wrote to them and asked for a list of these "specialists." I asked them what training do these specialists have, where do they get this training and by whom?

Despite many weeks of emails back and forth and the usual game of semantics played by the MHRA, they could not provide me with one specialist. The links to the launch of the SSRI Learning Module are below.

Now that is has been more than 7 years since I asked MHRA for a list of specialists and they couldn't list a single one, I pose the question again: Can MHRA provide a list of specialists who are trained to help patients safely withdraw from drugs labeled as "antidepressants."?  I also pose the same question for patients suffering from benzo withdrawal.

The New York Times article is long overdue but I suspect it may well be wrapping up someone's fish & chips tomorrow because that's how this works. Pleas for help go unanswered because the strategy from the psych and pharma industry is to shift blame and change the conversation. They aim to avoid honest discussion of these serious medical issues despite that discussion and awareness would reduce suffering and save lives.

If the Yugolslavia trials don't show you how corrupt this system is, your definition of corrupt is far different than Webster's

Bob Fiddaman


Yugoslavia Trial

The Seroxat/Paxil Yugoslavia Trial Part I

The Seroxat/Paxil Yugoslavia Trial Part II

SSRI Learning Module

MHRA To 'Re-educate' UK Doctor's on SSRi's Part I 

MHRA To 'Re-educate' UK Doctor's on SSRi's Part II "Keeping A Stiff Upper Lip" 

MHRA To 'Re-educate' UK Doctor's on SSRi's Part III - MHRA's Ghosts In The Machine 

MHRA In Buck-Passing Specialist Cahoots 

MHRA - More on the Mysterious "Ghost Specialists" 

MHRA Wishing To Call The Shots






Friday, April 06, 2018

Medicide: What's It All About & What Can We Do?



Natalie Gehrki
Today marks the 12 year anniversary of this blog and with over 2 million views since its conception I find myself posting a recent radio show asking "What can we do?" Over the years I've covered many advocates and their efforts to increase awareness so others might avoid dangerous ineffective drugs. I've covered wrongful death court trials, organizations dedicated to exposing psychiatry and pharma's deceit, tragic losses of life too numerous to count.

Today, I'd like to pose a question to my readers: What can we do? We all have diverse talents, compassion, wisdom that often comes from ADR experiences, and a commitment to positive change. Perhaps there are some great ideas for collaboration out there?

The following interview with Kristina Gehrki went out live on KCAA Radio on Wednesday evening. In it, she explains how she tragically lost her daughter, Natalie (19) to prescription drugs, namely Prozac and Zoloft.

You can download the interview here

Bob Fiddaman

Back Stories

Kidnapped: Natalie’s Story

Kidnapped: Natalie’s Story 2

Netherworld

Let's Bring Akathisia Out of the Darkness

Kristina Gehrki - Twitter





Tuesday, March 27, 2018

India: GSK Whistleblower Names and Shames - Part I




Navneet Kumar started his career with GSK India (Roorkee HQ) on March 2011 where he was assigned to meet doctors on daily a basis to persuade them to prescribe GSK drugs to their patients and to visit other Health Care Professionals (pharmacists, etc.) Kumar also used to organize 'Doctor Roundtable' meetings, and 'Continuing Medical Education' (CME) meetings for GSK product promotions. His job also saw him report to his Area Business Manager (ABM), Mr. Jitendra Singh Chauhan and indirectly to his Regional Business Manager (RBM), Sanjeev Jolly.

Kumar was awarded the 'Super Star' for his excellent sales performance and was given the opportunity to travel to Dubai (paid for by GSK). Many other sales awards were won by Kumar, and all seemed fine with his chosen career at GSK India, that was until he started to notice many irregularities, discrepancies, and became the victim of harassment for not adhering to the unethical sales pressures bestowed upon him by GSK management.

And now, Kumar no longer wants to remain quiet.

Kumar alleges that he and colleagues wrote to GSK Senior Management on the 29th December 2012 about a violation.

Septran (trimethoprim and sulfamethoxazole) is a combination of two antibiotics used to treat ear infections, urinary tract infections, bronchitis, traveler's diarrhea, methicillin-resistant Staphylococcus aureus (MRSA) and Pneumocystis carinii pneumonia. 

On each last working day of the month, Kumar collected orders from stockists. Stockists, according to Kumar, are people who are authorized to buy drugs directly from the company and supply those drugs to chemists or doctors whilst adding their 10% margin.

Kumar told me:

"Stockists buy drugs from the company. Now, let us take an example - GSK's branded drug Septran has a maximum retail price of 100 Rupees. The price to retailers (chemists, etc) costs around 23.5%, around 76 rupees. Now, the same drug will cost stockists 10% less, around 66 rupees because stockists directly buy from the company. 

"Now. it was my manager who was forcing drug reps to do an adjustment. An adjustment is where we have to establish a mutual understanding with stockists. We force them to sell drugs at lower prices like if something is costing them 66 rupees we have to force them to sell the drug on for 60 rupees or even less. This how extra sales will be done. 

"The difference will be paid to stockists by drug reps through their incentive bonus and some part of their salary. This is the cost of staying in the job at GSK.

Managers earn their incentives by threatening the reps. If a drug rep reaches his targets automatically managers will achieve their targets. But the drug rep has to make an adjustment so the money he earns will go to the stockists. Managers earn incentives without any hurdles."




By "hook or by crook"

Kumar alleges that his Regional Business Manager, Sanjeev Jolly (pictured above), told him to reach his sales targets by "hook or by crook". Further, Kumar alleges that Jolly threatened to take action against him if he "didn't do as he was told."

In a nutshell, Kumar tells me, Jolly was telling him to pay his stockist out of his own pocket whilst Jolly reaped the monetary benefits.

According to Kumar, the standard operating procedure at GSK specifies that a drug rep should not be involved in any money-related matters with their stockists.

Other GSK reps have, in the past, received the same kind of threats from Jolly, Kumar and, as a result, saw them write an email to top officials at GSK. According to Kumar GSK's sales reps complained when Jolly instructed them to place an order of 100 cases of Septran tablets.

A grievance meeting was conducted at GSK's New Delhi HQ, Jolly apologized and, well, that was that. GSK officials took no disciplinary action against Jolly.

Jolly's LinkedIn page can be found here - His tagline says that he is an "inquisitive marketeer with an undying thirst to learn and achieve."

According to Kumar, he was the most senior rep but after the grievance meeting against Jolly he was transferred from his hometown to Dehradun (another GSK HQ) in 2015 without any given reason. That's when the harassment started. Kumar told me, "He started harassing me with the help of two Area Business Manager's (ABM), Jitendra Singh Chauhan and Manish Sachdev. They collaborated in handing me a Dealer list on which achieving the company objective was very difficult. Chauhan also sent me unnecessary emails and pressured me to carry out unethical work practices."

This harassment didn't stop at Jolly. Kumar told me that his ABM, Jitendra Singh Chauhan, "...took a massive advantage of his position. He used to send me phone messages at midnight, non-working days and holidays. He used to call me from his home for personal work. When I started objecting to his unnecessary demands, he started taking advantage of his position to harass me even more. He created false allegations against me and started making his own rules whilst overlooking the company guidelines."

Chauhan (Seen below as 'ABM Boss' (1)) told Kumar he wanted him to call 12 dealers per day. The company guideline, however, stipulates that reps will meet no more than 6.5 dealers per day (2)


(1)

(see Work Norms/Rules a) and e(i)
CLICK ON IMAGE TO ENLARGE


(2)

"I will finish your career, you and your family will be out on the street."

In effect, Chauhan was almost doubling the workload of Kumar, who believes the unrealistic request to target 12 dealers a day was an effort to get him to resign. I've seen many screenshots of the text messages and, it appears, Chauhan was, in many instances,  sending messages just before and after midnight.

Kumar, despite the demands being put on him, decided to continue working, he would not resign. 

Sometime later, however, he was called into a meeting at GSK's New Delhi office by Sanjeev Jolly. Kumar told me:
"I thought he called me for in for a training program . In a closed room he gave me a white paper and I was asked to submit my resignation. I was shocked and refused to resign. He started threatning me and told me "I will finish your career" and that, "You and your family will be out on the street." He also told me that he will not allow any company to recruit me.
"I was under immense pressure to resign but I didn't. I asked him to provide reasons for why he is doing all these things. Then he presented a charge-sheet in front of me and, once again, asked me to resign. I decided to go with the charge-sheet rather than resignation. He (Jolly) did the same thing with my ex-colleague some months previously, he, like me, was called to the New Delhi office, and under pressure from Jolly, he resigned. This a pattern by GSK management to threaten the employee and they usually resign because the pressure is overwhelming for them. I didn't do that."

Coming up in Part II


  • How Navneet alleges that there is no code of conduct amongst GSK India's senior management
  • More evidence of retaliation and harassment
  • Alleged forgery by GSK management
  • Emails to former GSK CEO, Andrew Witty, GSK's Global Head of Investigation, Jason Lord, and current CEO, Emma Walmsley, and some other top officials of GSK
  • For the first time, Kumar will reveal a document that, so far, has been unseen by the public.


Bob Fiddaman

Back story - Truthman Blog




Thursday, March 22, 2018

GSK's Nutcracker Dilemma





nutcracker
A tough woman who, when provoked, will literally crack your nuts. - Urban Dictionary (5)


GSK has been delivered a swift kick in the gonads regarding the Dolin Vs GlaxoSmithKline appeal process.

The company was held liable in April 2017 when a jury found it responsible for the labeling on their Paxil product as well as generic equivalents.

Ever since then GSK, via their hired attorneys, King & Spalding, has been crying like big babies. Motions have been filed whereby they blame the jury. Motions have been filed whereby the blame the Judge too.

In fact, since this case first came to light GSK have blamed everyone but themselves, including the victim, Stewart Dolin, his doctor, and even the FDA!

Now they have someone else to blame, namely the States of California and Massachusetts.

In a decision released last Friday in Rafferty v. Merck, case number SJC-12347, the Massachusetts Supreme Judicial Court ruled that brand-name drug makers can be sued for recklessness if they intentionally fail to update warning labels for their products that makers of generic versions must also adopt. Rafferty had alleged that he suffered from side effects, including sexual dysfunction, after taking the generic version of Merck’s Proscar. Rafferty's case against Merck was previously thrown out but the ruling was reversed last week, allowing Rafferty to sue Merck for recklessness rather than negligence.

Recklessness basically means the claimant has to show that a drug maker intentionally failed to update its warning label despite knowing the risks. This was already proven in the original Dolin Vs GSK case; hence the jury reached a decision that found GSK liable. The jury found for Dolin and awarded her $3 million. However, she has not seen a penny as GSK has filed motion after motion in efforts to avoid paying and have the judgment overturned. Now the recent Massachusetts decision means GSK will have to rethink their strategy, possibly by blaming Wendy Dolin's next door neighbor's cat!

Back in December 2017,  the California Supreme Court also ruled that brand-name drug makers can be sued for failing to warn users about the risks of generic versions of their drugs.

It's not looking good for GSK as their appeal to the Seventh Circuit to overturn the Dolin verdict seems dead on arrival. Today's news is great for Dolin's attorneys, Baum Hedlund, who are now also looking to help consumers who have attempted suicide whilst taking paroxetine manufactured by Apotex.

Back stories of how the Dolin trial unfolded below.


Bob Fiddaman

Dolin v GSK - Opening Arguments

Dolin Vs GSK - Day Two - "Jack-In-The-Box"

Dolin vs GSK - Healy 'Rocks Da House'

Dolin Vs GSK - JP Garnier Video Deposition

Dolin Vs GSK - The Dunbar Tape

Dolin Vs GSK - Day 4 - Slam Dunk

Dolin Vs GSK - 8.9 Suicide Increase For Adult Paxil Users

Dolin Vs GSK - Day 6 - Ass Kicking Semantics

Dolin Vs GSK - Day 7 - Abraham Lincoln

Dolin Vs GSK - Day 8 - Get to the Point, Todd!

Dolin Vs GSK - Glenmullen Nails It!

Dolin Vs GSK - "Babes"

Dolin Vs GSK - Wendy's Cross and GSK's Petition

Dolin Vs GSK - Robert "Bling Bling" Gibbons

Dolin Vs GSK: Suicide Prevention Warning "Futile", Claims GSK Exec

Dolin Vs GSK: Jury shown List of the Dead in Paxil Clinical Trials

Dolin Vs GSK: Last Man Standing & The Return of Dr. Healy

Dolin Vs GSK: Closing Arguments

Dolin Vs GSK - The Verdict

Exclusive: Interview With Wendy Dolin


From Chicago to New York - The Legacy of Stewart Dolin

Dolin Wins...Again

Dolin Vs GSK: Personal Vendetta or Bigger Picture?


GSK's Attorney Labels His Failure An "Accomplishment"

Generic Paxil Lawsuits Filed




Sunday, March 18, 2018

Is This The World We Created?



You know that every day a helpless child is born
Who needs some loving care inside a happy home
Somewhere a wealthy man is sitting on his throne
Waiting for life to go by.

Is this the world we created?
We made it on our own.
Is this the world we devastated
Right to the bone?

If there's a God in the sky looking down,
What can he think of what we've done
To the world that He created?

'Is This The World We Created?'
Mercury, May



I'm dumbfounded and disappointed at recent events in the business of psychiatry. Why is the blindingly obvious ignored or downplayed by people in positions of power-positions that could be used to save human suffering and lives?

This isn't intended to target psychiatrist and Royal College of Psychiatrists spokesperson, Carmine Pariante. I've been pleasantly surprised that in recent weeks Pariante has been open for civil discussion shown on Twitter.He appears to understand the need for informed consent and has even suggested that drug safety advocates work alongside psychiatry. I have to give him a hearty round of applause for not taking the stance many psychiatrists take on Twitter. That is, they cry "pill-shaming" when a victim of "antidepressant" ADRs speaks out. Others simply block patient advocates who share research and experiences via Twitter.  (See ~ Who's Hiding the Clinical Trial Benefits of Antidepressants?)

However, what I do take umbrage with is Pariante's recent stance on an article I sent to him via his Twitter feed. The article, from journalist, Kirstie Brewer, was featured on the BBC website and entitled, 'I was suicidal - the NHS didn't know what to do with me'.

It's important to click on the link (here) to review this article as it is the same link I sent to Pariante asking if he thought it was possibly drug related? (1)


(1)

Notice my use of the word 'possibly' in the tweet. I wasn't categorically stating that the young woman featured in the article had attempted suicide because of the meds she was prescribed since age 13. (After re-reading the article, I learned that she was 13 and not 11.) I was just opening a dialogue about ADRs and causation. However, in this instance, it seemed Pariante didn't want to play ball with me. (2) (3) (4)

(2)


(3)

(4)

I was dumbfounded that Pariante wouldn't even entertain the possibility that the young woman featured in the article could have been suffering from psychosis as a result of the drugs she had been prescribed from a young age. Instead, he shifted the conversation suggesting that neither he or I knew any clinical details regarding this young woman. That may be so but here's some selective text taken from the article that begs the question, "What is Pariante failing to see here?" The relevant points are in bold font.

It was the ninth time in the space of 10 days that Sherry Denness had tried to kill herself. "It felt like checkmate - there were no open doors or other ways for my life to turn, I just wanted to die," she says.

Only just 18, Sherry has been diagnosed with a number of mental health conditions, including borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD).

On seven of her nine suicide attempts, which took place in November last year, the teenager had landed in A&E, been patched up and deemed well enough to be sent home with no further help. Another time she'd taken all of her prescribed medication in one go and ended up in critical care for two days. 

"I was psychotic and I was hearing Kieran in my head telling me I need to leave the house." Kieran is one of the voices Sherry hears - the worst one, she says.

She was 11 when she was first assessed by the Child and Adolescent Mental Health Services (Camhs.) Eventually, at 13, she was given treatment for ADHD.

"I have been to A&E a lot of times for self-harm and suicide attempts", Sherry Says.

With all these references in plain sight, I find it remarkable and quite telling that Pariante refuses to accept the 'possibility' that her deterioration might be drug-related.

Let's take a look at a research study (SSRI - Induced Extrapyramidal Side-Effects And Akathisia Implications for Treatment) from almost 20 years ago. It was authored by Roger Lane and featured in J Psychopharmacol.1998;12(2):192-214.review

A note of interest here: Between 1992 - 2001 Roger Lane was the Senior Medical Director at Pfizer. Today he is the Vice President, Clinical Development Neurology for Ionis Pharmaceuticals.

Lane wrote:
“It has been suggested that SSRI-induced akathisia may be associated with the emergence of ego-dystonic suicidality (Lipinski et al., 1989: Rothschild and Locke, 1991: Hamilton and Opler, 1992). The most consistent factor implicated in these anecdotal accounts of rare adverse reactions involving suicidal ideation and behavior during fluoxetine treatment was the development of akathisia with agitation, restlessness and dysphoria (Power and Cowen, 1992).”
“It may be less of a question of patients experiencing fluoxetine-induced suicidal ideation, than patients feeling that ‘death is a welcome result’ when the acutely discomforting symptoms of akathisia are experienced on top of already distressing disorders."
During the 20 years in which this word, 'Akathisia' was mentioned, there have been many deaths by suicide whilst patients have been on prescription drugs. On one side of the fence, we have psychiatrists who claim that the SSRI/akathisia link is not proven despite the research and causation admission noted above. On the other side, we have loved ones whose family members, including children and young adults, have had psychotic reactions to SSRIs that precipitated unimaginably violent deaths.

When faced with possibilities of causation, Pariante should be stepping up to the plate and looking into SSRI-induced psychosis. He should, at the very least, acknowledge the possibility that these drugs can and do precipitate psychosis and death for unsuspecting ADR victims.

Last year the subject of drug-induced akathisia was highlighted in Chicago in the case of Dolin Vs GSK. The transcripts and trial exhibits have now been made public for more than a year (See the right-hand side of this blog). During the trial, it was learned that the victim, Stewart Dolin, leaped to his death because he was suffering from drug-induced akathisia. After a 6-week long trial, the jury found for the plaintiff, Stewart's wife, Wendy. They carefully reached this verdict after hearing 6 weeks of evidence presented by both Dolin and GSK.

Another active Twitter psychiatrist is Duncan Double. Double disputes that SSRIs can induce akathisia and after sending him a link to the Dolin transcripts and trial exhibits he had this to say:

"Legal judgment is not necessarily the same as scientific fact."

Upon informing him, the jury sat through six weeks of evidence Double remarkably replied:

"One doesn’t know which bit of evidence the jury based its decision on."

I told him good jury's don't base a decision on one bit of evidence, they base it on all.

Hours later, Double tweeted:




Nice, and kind of big of the man to state that he was wrong. This, however, didn't last for long as later in the day he bizarrely stated, "I’d still like to debate whether I might  be right."

So, just two instances of psychiatry at work here.

I'm not definitively claiming that the young woman featured in the BBC news article tried to take her life because the "drugs made her do it." There may be other mitigating circumstances. You see, I'm open to other possibilities whereas, it appears, Pariante and Double are not, despite Pfizer's own scientist stating, "death is a welcome result’ when the acutely discomforting symptoms of akathisia are experienced."

I wrote a book back in 2011 called, "The Evidence, However, is Clear." It would appear I was wrong because, for some, the evidence is invisible. Yet sometimes we find ADR evidence that was unwittingly documented by people who are no longer visible but speak from the dead. I'm talking about a diary kept by a young woman who, just like the young woman featured in the BBC article, was harmed by a medical field whose diagnoses are largely based on guesswork.

Natalie Gehrki was just a year older than the woman featured in the BBC article noted above. There are striking similarities between both, and we can learn much from the experiences of each young woman. Natalie was prescribed the SSRI, Zoloft, NOT for "depression." She never received any specific diagnosis at the time of her death. Doctors who are unfamiliar with akathisia and serotonin toxicity often don't take the correct steps to stop it. Natalie died less than two days after her doctor increased Zoloft-over the phone to the maximum legal dose allowable, 200mgs.

There are many more Natalie's out there, some dead and some still alive. We owe it to them to warn of akathisia. If two publically renowned psychiatrists won't discuss SSRI-induced akathisia and the necessary steps to prevent akathisia & SSRI deaths, we must rely on teenagers with first-person insight and no conflicts of interest.

Dr. Oz's Fantasy World

On a related note, last week Dr. Oz ran a show that was supposed to be a serious examination of the connection between drugs and violence. It was shockingly bias and omitted critical information. Natalie's mom, Kristina, was one of many viewers who wrote to the Dr. Oz producer. Her letter is beneath the video.

Here's Natalie.




And here's Natalie's mother, Kristina, writing to the producer of the Dr. Oz show.

Dear Ms. Varney,

I'm writing to express my shock and dismay regarding Dr. Oz's recent show about drugs & violence. As a trained journalist, I expected a variety of experts would discuss reliable data, relevant pharma documents, legal cases and consumers' reported ADR experiences. Instead, I quickly learned your panel of three  "experts" all had ethical &/or financial conflicts of interest. While Dr. Oz casually and promptly glossed over these conflicts, declaring conflicts of interest does not remove these conflicts of interest.

I waited in vain to hear from experts with opposing viewpoints to the pharma-connected panel. But few of these experts were featured and those that were received minimal air time. This includes Wendy Dolin, founder of MISSD. When you flashed on the screen the 3 million settlement a jury awarded for her husband's prescribed Paxil death, it was misleading and offensive. Not only has Ms. Dolin not received a penny from GSK after the jury's wrongful death award, it was beyond the pale to flash a cash amount on the screen. Such sensationalized antics are akin to a sordid game-show gimmick.

Given your producers felt this financial info was necessary for viewers to know, I pose the question: Why didn't you similarly treat your panel in the same manner? When Dr. Oz was glossing over conflicts of interest; you could have visually informed your viewers of the amount of money each panel member has already taken from pharma. Your slanted, one-sided journalism has been the topic of much negative discussion on many social media feeds. But even if the public didn't notice the appalling bias, as a producer you should have recognized such before airing.

Lastly, aside from a professional and academic background in journalism and crisis communication, I am the mother of a 19-year-old daughter whose death was precipitated by another SSRI (Zoloft). Medical experts determined Natalie was suffering from prescribed akathisia and serotonin toxicity prior to her death. After death blood tests showed she could not efficiently metabolize SSRI toxins. Her prescribed tragedy is found at https://rxisk.org/kidnapped-natalies-story/ and https://www.youtube.com/watch?v=1haYwZGcSRY 

Your irresponsible journalism was a disservice to public health and safety. Undoubtedly, it will cause avoidable suffering and more ADR-related deaths. Nothing can change the damage caused by the show you produced. Nevertheless, you have an ethical obligation to apologize and air a follow-on show that transparently shares unbiased accurate data in a fair and balanced manner.

Regards,
Kristina Gehrki

--

Bob Fiddaman




Friday, March 16, 2018

67.5 million antidepressants - Joining The Dots




To put this into context, since I've been blogging about the dangers of antidepressants, the prescription rates for them have risen by over 30 million. Yet I'm 'scaremongering' or 'pill-shaming', further, I'm a 'smeary conspiracy theorist'. All labels thrown at me by people who believe I'm wrong. I'm even criticized because I have no medical background. All efforts to silence me have failed.

Yet the carnage continues...

Do the maths then read the link at the foot of the pictures. If you still can't join the dots then I respectfully suggest a new pair of reading glasses.


Prescriptions - Rising

Mental Health Conditions - Rising

Suicides Since 2007 - Rising



The article below (15 March 2018) features a quote from Matt Blow, a policy manager at YoungMinds. I've omitted the comment but you can read it by clicking on the link at the foot of this summary.

YoungMinds is, according to their website, "the UK’s leading charity championing the wellbeing and mental health of young people." They claim, amongst other things, that depression is caused by a chemical imbalance in the brain. Further, they claim medication "can help to address chemical imbalances and make someone feel more ‘normal’"



'I tried to kill myself nine times before the NHS helped me'

It was the ninth time in the space of 10 days that Sherry Denness had tried to kill herself. "It felt like checkmate - there were no open doors or other ways for my life to turn, I just wanted to die," she says.

Only just 18, Sherry has been diagnosed with a number of mental health conditions, including borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD).

On seven of her nine suicide attempts, which took place in November last year, the teenager had landed in A&E, been patched up and deemed well enough to be sent home with no further help. Another time she'd taken all of her prescribed medication in one go and ended up in critical care for two days. 

"I was psychotic and I was hearing Kieran in my head telling me I need to leave the house." Kieran is one of the voices Sherry hears - the worst one, she says.

She was 11 when she was first assessed by the Child and Adolescent Mental Health Services (Camhs)

Eventually, at 13, she was given treatment for ADHD.

"I have been to A&E a lot of times for self-harm and suicide attempts", Sherry Says.


What was the total of your sum, folks?

Answers on a postcard to The Royal College of Psychiatrists.

Bob Fiddaman

Graphs courtesy of James Moore





Sunday, March 11, 2018

GSK Whistleblower Spills The Beans To Blogger






After a three month hiatus, GSK Licence To Kill blogger, the Truthman, has come back with all guns blazing.

He's been contacted by a Whistleblower from GSK India who has a series of allegations that may be worrisome for GSK CEO, Emma Walmsley.

Amongst the allegations are:

"His area manager was asking for personal favors and he wanted the rep to give him money (back-handers). For example: he wanted the rep to pay the school fees of his children (the whistle-blower has screenshots- proof)- and his rent- from the rep’s salary. The rep pleaded that it was ‘not in the culture of GSK’ to pay back-handers to area managers- and that he worked for GSK and not the area manager. The manager was relentless in his pursuit of these backhanders, often harassing the rep whenever he chose.
The rep/whistle-blower refused to pay backhanders and engage in fraud, and  because of this he was harassed, bullied and eventually set up with false charges- which led to his termination."


The allegations come hot on the heels of the Serious Fraud Office announcement late last year that they will be soon finished an investigation of corruption and fraud into GSK's foreign practices.

Maybe they need to hold the front page as Truthman releases more information on GSK's antics in India?

For more of GSK India's dirty deeds, head on over to the exclusive at  GSK : Licence To (K) ill


Bob Fiddaman



Please contact me if you would like a guest post considered for publication on my blog.